Zobrazeno 1 - 10
of 51
pro vyhledávání: '"B. I. Rini"'
Autor:
Mayer Fishman, Jamal Tarazi, Viktor Grünwald, Eric Jonasch, Yoshihiko Tomita, Thomas E. Hutson, A.H. Blair, Laura Cisar, Brad Rosbrook, M.D. Michaelson, B. I. Rini
Publikováno v:
Annals of Oncology. 27:vi287
Publikováno v:
Cancer. 95(8)
BACKGROUND The objective of this study was to determine the clinical response rate of the combination of weekly intravenous (IV) gemcitabine with continuous infusion fluorouracil (5-FU) and daily oral thalidomide in patients with metastatic renal cel
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 13(1)
Background We reported previously that the combination of gemcitabine and continuous infusion fluorouracil (5-FU) has activity in renal cell carcinoma [1]. Based upon in vitro synergy of gemcitabine/cisplatin and 5-FU/cisplatin, we hypothesized that
Publikováno v:
The Journal of urology. 165(4)
Autor:
B I, Rini, N J, Vogelzang
Publikováno v:
Seminars in oncology. 27(2)
Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(10)
Renal cancer cell lines exhibit deficient expression of MHC class I antigens required for appropriate CTL stimulation. Nabel et al. (Proc. Natl. Acad. Sci. USA, 90: 11307-11311, 1993) demonstrated that direct gene transfer of the deficient class I MH
Publikováno v:
Cancer. 82(7)
Due to lack of success with standard chemotherapy and only modest success with immunotherapy, metastatic renal cell carcinoma (RCC) is associated with a poor prognosis. Granulocyte-macrophage-colony stimulating factor (GM-CSF) is a cytokine with pote
Autor:
H. Bhattacharyya, David Cella, B. I. Rini, Bernard Escudier, Connie Chen, Jamal Tarazi, Robert J. Motzer, Sinil Kim, Brad Rosbrook
Publikováno v:
Journal of Clinical Oncology. 29:4504-4504
4504 Background: In a global, randomized, phase III trial of axitinib vs sorafenib as second-line therapy for mRCC (Rini et al, ASCO 2011), axitinib was superior to sorafenib in the primary endpoint of median progression-free survival (PFS) (6.7 vs 4
Autor:
M.D. Michaelson, Michael A. Tortorici, T. de La Motte Rouge, Paul Bycott, Robert J. Motzer, Antonella Ingrosso, Andrea L. Harzstark, B. I. Rini, Viktor Gruenwald, Sinil Kim, Glenn Liu
Publikováno v:
Journal of Clinical Oncology. 29:4547-4547
4547 Background: Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3. Axitinib in patients (pts) with cytokine-refractory mRCC (Rixe et a...
Autor:
Thomas E. Hutson, C. Szczylik, Sinil Kim, Robert J. Motzer, Bernard Escudier, Brad Rosbrook, Jamal Tarazi, Andrey Kaprin, Piotr Tomczak, B. I. Rini
Publikováno v:
Journal of Clinical Oncology. 29:4503-4503
4503 Background: Axitinib is an oral, potent, and selective inhibitor of VEGF receptors 1, 2, and 3. This randomized, open-label, phase III trial compared the efficacy and safety of axitinib versus (vs) sorafenib as second-line therapy for mRCC. Meth